COVAXX has started dosing healthy adult participants in a Phase I clinical trial of its Covid-19 vaccine candidate, UB-612, in Taiwan.

The dose-escalation study received funds worth approximately $15m from the Ministry of Health and Welfare in Taiwan.

UB-612 is a multitope peptide-based vaccine candidate that is meant to activate the B and T-cell arms of the immune system.

It is developed via genetic fusion of the Spike protein S1 subunit receptor-binding domain (RBD) to a single chain Fc domain of human IgG1 (S1-RBD-sFc).

The open-label Phase I trial will test the safety, tolerability and immunogenicity of the vaccine candidate. It is recruiting 60 healthy adults aged 20-55 across three arms, which will have 20 participants each.

Each participant will be given ascending dose levels of UB-612 in two intramuscular injections administered 28 days apart.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Immunological tests will be conducted to assess the candidate’s protective activity. The Laboratory of Molecular Virology and Viral Immunology at Academia Sinica in Taiwan will carry out the neutralisation titre analysis.

COVAXX co-CEO Mei Mei Hu said: “Administering the initial dose of our vaccine candidate to the first participants not only marks the start of this Phase I clinical trial but also represents a significant step forward in the global fight against Covid-19.”

This trial expands COVAXX’s global partnerships following deals with diagnostic medicine company Dasa and The University of Nebraska Medical Center for large scale human efficacy studies in Brazil and the US, respectively.

COVAXX chief scientific officer Farshad Guirakhoo said: “Producing a safe and effective Covid-19 vaccine within the next 12 to 18 months is not only a challenge but it also requires new levels of collaborations across healthcare industries and governments worldwide.”

The results of the Phase I trial will be analysed to determine an appropriate dose and advance the vaccine candidate to a Phase II/III trial.